MERTK and neoplasm: The research has demonstrated that inhibiting MERTK reduces the presence of PD-L1 in the TME, thereby limiting tumour cells' ability to elude the immune system [33].Various tumour cells predominantly express PD-L1 on their surface, while immune cells like DCs and macrophages commonly detect PD-L2.